2-二乙基氨基乙基4-丁基氨基苯甲酸酯 | 3772-42-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-二乙基氨基乙基4-丁基氨基苯甲酸酯
• 英文名称: 4-butylamino-benzoic acid-(2-diethylamino-ethyl ester)
• 英文别名: 4-Butylamino-benzoesaeure-(2-diaethylamino-aethylester)；4-butylamino-benzoic acid-β-diethylaminoethyl ester；diethylaminoethyl p-butylaminobenzoate；tetracaine；2'-Dimethylaminoaethyl-4-butylamino-benzoat, Tetracain, Pantocain；4-Butylamino-benzoesaeure-(2-diethylamino-ethylester)；Farmocaine；2-(diethylamino)ethyl 4-(butylamino)benzoate
• CAS: 3772-42-7
• 化学式: C₁₇H₂₈N₂O₂
• 分子量: 292.422
• InChiKey: JQMCLLAJJLVYOC-UHFFFAOYSA-N

物化性质

• 熔点：
  108-109 °C (decomp)
• 沸点：
  434.34°C (rough estimate)
• 密度：
  0.9876 (rough estimate)
• 保留指数：
  2350;2375

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922499990

反应信息

• 作为产物：
  描述：

  正丁醛 、 普鲁卡因 在 哌啶乙酸盐 、 镍 作用下， 生成 2-二乙基氨基乙基4-丁基氨基苯甲酸酯
  参考文献：
  名称：

  DE716668

  摘要：

  公开号：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY<br/>[FR] COMPOSES HETEROCYCLIQUES, PROCEDES DE PRODUCTION DE CEUX-CI ET UTILISATION DE CEUX-CI DANS UN TRAITEMENT
  申请人：AFFINIUM PHARM INC

  公开号：WO2004052890A1

  公开（公告）日：2004-06-24

  In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

  在某种程度上，本发明涉及公式（I）的抗菌化合物，其中A是一个双环杂芳基环或三环环，R2是一个杂环残基；L是一个键，或者L是烷基，烯基或环烷基。
• External Preparation Containing NSAIDs And Method For Producing The External Preparation
  申请人：Tei Yuichi

  公开号：US20120135955A1

  公开（公告）日：2012-05-31

  Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor.

  本发明涉及一种含有非甾体抗炎药（NSAIDs）的外用制剂，该制剂被抑制了由NSAIDs引起的细胞毒性。同时还公开了一种制备该外用制剂的方法。本发明基于以下发现：当NSAIDs与双糖中的海藻糖等分子形成分子间化合物时，可以抑制由NSAIDs引起的皮肤疾病。因此，本发明中也可以使用海藻糖以外的其他双糖。
• External Preparation Containing NSAIDS And Method For Producing The External Preparation
  申请人：Next21 K.K.

  公开号：US20140336144A1

  公开（公告）日：2014-11-13

  Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor.

  本发明涉及一种含有非甾体类抗炎药（NSAIDs）的外用制剂，该制剂能够抑制NSAIDs诱导的细胞毒性。同时，本发明还涉及一种制备该外用制剂的方法。本发明基于以下发现：当NSAIDs与二糖之一的海藻糖形成分子间化合物时，可以抑制NSAIDs引起的皮肤疾病。因此，也可以使用其他二糖。
• A multi-layered film preparation
  申请人：SANWA KAGAKU KENKYUSHO CO., LTD.

  公开号：EP0781546A1

  公开（公告）日：1997-07-02

  A multi-layered film preparation has a drug containing layer which contains a water-soluble high molecular weight substance as a main base material, has on one surface thereof a layer difficult to dissolve in water, and carries on the other surface an adhesive substance or contains therein the adhesive substance in a dispersed state. The film preparation is easy in handling thereof and shows good adhesiveness to the mucous membrane in the oral cavity, even if it has been remarkably moisted, and gives no bad feeling in use.

  一种多层膜制剂具有含药层，该层含有水溶性高分子量物质作为主要基材，在其一个表面上有一层难溶于水的层，在另一个表面上带有粘合剂物质或其中含有分散状态的粘合剂物质。 这种薄膜制剂易于操作，即使在明显潮湿的情况下也能与口腔黏膜保持良好的粘附性，使用时不会产生不良感觉。
• Method of treating lower urinary tract disorders
  申请人：Dynogen Pharmaceuticals, Inc.

  公开号：EP1795196A2

  公开（公告）日：2007-06-13

  The invention relates to the treatment of at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, and wherein to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity is to be administered. The invention further relates to the treatment of at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

  本发明涉及需要治疗的受试者至少一种下尿路疾病症状的治疗，其中该症状选自由尿频、尿急、尿失禁、夜尿和遗尿组成的组，并且对需要治疗的受试者施用治疗有效量的具有5-HT3受体拮抗剂活性和去甲肾上腺素再摄取抑制剂（NARI）活性的化合物。本发明进一步涉及对需要治疗的受试者的至少一种下尿路疾病症状的治疗，其中该症状选自由尿频、尿急、尿失禁、夜尿和遗尿组成的组，包括向所述受试者联合施用第一量的5-HT3受体拮抗剂和第二量的NARI，其中第一量和第二量共同组成治疗有效量或各自以治疗有效量存在。